Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Applera Files Complaint and Notice of Arbitration Against F. Hoffman-La Roche Ltd. Over Rights to PCR Technology

Norwalk, CT - October 13, 2003

Applera Corporation (NYSE:ABI/CRA) today announced that it has filed a complaint in California Superior Court, County of San Mateo, relating to disputes arising from various contractual relationships with F. Hoffmann-La Roche Ltd. (Roche) and certain Roche subsidiaries. In a separate action involving Roche, Applera has also filed a notice of arbitration with the American Arbitration Association. Both actions involve rights to and commercialization of polymerase chain reaction (PCR) technology.

“PCR, a technology for amplifying and analyzing DNA, is an enabling technology for biological research, and rights to PCR are part of the intellectual property estate of Applera Corporation,” said Michael W. Hunkapiller, Ph.D., President, Applied Biosystems Group and Senior Vice President of Applera. “With these actions, Applera is seeking to protect its rights to PCR and obtain fair value from these rights. Because contract disputes in our field are often complex, barring a settlement, it may take some time before these actions will be resolved by the courts and by arbitration.”

About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2003. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery System™ online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at, or by telephoning 800.762.6923. Information about Applied Biosystems is available at

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.